Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 29
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Moleculin Biotech Inc
MBRX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$8.72
-0.025
-0.29%
Últ. Act.: Oct 29, 8:11 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Moleculin Biotech Financials
Moleculin Biotech (MBRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of $(12.25) per share
Benzinga Newsdesk
PRO
Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the analyst consensus estimate of $(1.57) by 125.48 percent. This is a 77.59 percent increase over losses of $(15.80) per share
Benzinga Newsdesk
PRO
Moleculin Biotech Q4 EPS $(26.06) Misses $(11.60) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(26.06) per share which missed the analyst consensus estimate of $(11.60) by 124.75 percent. This is a 181.73 percent decrease over losses of $(9.25) per
Benzinga Newsdesk
Nasdaq Surges 100 Points; Dollar General Earnings Beat Views
Avi Kapoor
US Stocks Mixed; Nvidia Posts Upbeat Earnings
Avi Kapoor
PRO
Moleculin Biotech Q2 EPS $(0.49) Misses $(0.42) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.42) by 16.67 percent. This is a 71.18 percent increase over losses of $(1.70) per share
Benzinga Newsdesk
